(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 October 2009 (22.10.2009)

PCT

(10) International Publication Number
WO 2009/127944 A8

(51) International Patent Classification:
C07D 211/70 (2006.01) *A61P 29/00* (2006.01)
C07D 401/12 (2006.01) *A61P 25/00* (2006.01)
C07D 413/12 (2006.01) *A61P 9/00* (2006.01)
A61K 31/4427 (2006.01)

(21) International Application Number:
PCT/IB2009/005246

(22) International Filing Date:
9 April 2009 (09.04.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/045,899 17 April 2008 (17.04.2008) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FAY, Lorraine Kathleen** [IE/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CTl 39NJ (GB). **JOHNSON, Douglas Scott** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton Connecticut 06340 (US). **MEYERS, Marvin Jay** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield Missouri 63017 (US). **THORARENSEN, Atli** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield Missouri 63017 (US). **WANG, Lijuan Jane** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield Missouri 63017 (US).

(74) Agent: **RICHARDSON, Peter, C.**; Pfizer Inc., 150 East 42nd Street, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
9 December 2010

(15) Information about Correction:
see Notice of 9 December 2010

(54) Title: ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS



(I)

(57) Abstract: The present invention relates to compounds of Formula (I) wherein Ar is optionally substituted phenyl or 6-membered heteroaryl moiety, or a benzisoxazole, pyrrolopyridine, or benzotriazole group; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, including pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.

WO 2009/127944 A8